Jan Peter Mattsson
Founder at ALBIREO PHARMA, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronald Cooper | M | 61 |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom.
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 9 years |
| Per-Göran Gillberg | M | 68 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 26 years |
| Mike Gutch | M | 58 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 9 years |
| Roger Jeffs | M | 62 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 6 years |
| David Chiswell | M | 70 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 17 years |
| Davey Scoon | M | 78 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 11 years |
| Anne Klibanski | M | 73 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 5 years |
| Maria Charlotte Fribert | M | 57 | - | |
| Ann-Charlotte Rosendahl | F | 61 | 4 years | |
| Alan Sokaler | M | - | - | |
| Michelle Graham | F | 57 | 5 years | |
| Paul Streck | M | 60 | 2 years | |
| Christelle Huguet | M | 57 | 1 years | |
| Joan Connolly | F | - | 3 years | |
| Colleen Alabiso | F | - | - | |
| Kristian Sandberg | M | 63 | 7 years | |
| Muffy Carter | F | 71 | 8 years | |
| Thomas Pålsson | M | 72 | 1 years | |
| Björn Löwenadler | M | 72 | - | |
| Jennifer Benenson | F | - | 1 years | |
| Eva Lindgren | F | 74 | 6 years | |
| Heather White | F | - | 1 years | |
| Vidar Wendel-Hansen | M | 65 | 6 years | |
| Thomas Bengt Eldered | M | 64 | 3 years | |
| Aymeric Le Chatelier | M | 55 | 1 years | |
| Maarten Kraan | M | 63 | 6 years | |
| François-Maurice Garnier | M | 62 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas A. Shea | M | 64 | - | |
| Denise Scots-Knight | M | 64 |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | 9 years |
| Kristina Torfgård | M | 61 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 5 years |
| Julia Brown | F | 76 | 2 years | |
| Jason G. Duncan | M | 50 | - | |
| Stephanie Okey | F | 64 | 5 years | |
| Habib Dable | M | 54 | 1 years | |
| Susan Alesina | F | 61 | 1 years | |
| Simon Harford | M | 64 | - | |
| Peter A. Zorn | M | 53 | 3 years | |
| Heather Elizabeth Preston | M | 58 | 10 years | |
| Anders Harald Milton | M | 76 | 3 years | |
| Ingrid Påhlman | M | - |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | - |
| Paresh N. Soni | M | 63 | 2 years | |
| Torbjörn Sannerstedt | M | 64 | 1 years | |
| Björn Erlandsson | M | - |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | - |
| Craig Hopkinson | M | 56 | 1 years | |
| John Dadurian | M | - | 3 years | |
| Pamela Stephenson | F | 56 | - | |
| David Wahlund | M | 44 | 2 years | |
| Constantine Chinoporos | M | 57 | 2 years | |
| Patrick Taylor Horn | M | 69 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 35 | 71.43% |
| Sweden | 20 | 40.82% |
| United Kingdom | 4 | 8.16% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jan Peter Mattsson
- Personal Network